Bruker Corp

BRKR has broken below its intermediate EMAs and horizontal support, indicating structural weakness. Medium-term directional asymmetry favors further downside toward the 50-day SMA, but RSI near oversold and extended price suggests potential for a short-term bounce, warranting deferred bearish execution. Under a High Momentum strategy, trims should target rallies into the 9/20-day EMA resistance zone.

• ↑Q2 revenue $839M (+5.2% YoY) driven by 10% organic scientific instrument bookings.
• ↑Non-GAAP EPS $0.49 (+53% YoY) and operating margin expanded to 14.1%.
• ↓Persistent U.S. academic order weakness drags overall organic revenue growth.